Following on from information provided to NICE by the company in June 2016, the appraisal of Drisapersen for the first-line treatment of Duchenne’s muscular dystrophy [ID911] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process HST
ID number 911

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in June 2016, the appraisal of Drisapersen for the first-line treatment of Duchenne’s muscular dystrophy [ID911] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
28 June 2016 Suspended. NICE is considering an evaluation of drisapersen for treating Duchenne muscular dystrophy. The Institute has now been informed by the company that it has withdrawn its Marketing Authorisation for drisapersen in this indication, from the European Medicines Agency. Therefore, NICE has decided to suspend this evaluation on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development
28 June 2016 Draft scope documents

For further information on our processes and methods, please see our CHTE processes and methods manual